On December 2, 2025 Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, reported it will present two posters on the ELA026 clinical program in secondary hemophagocytic lymphohistiocytosis (sHLH) at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 6-9 in Orlando, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A trial-in-progress poster, presented by Dr. Swaminathan Iyer (MD Anderson Cancer Center), will highlight the SURPASS Phase 2/3 pivotal clinical study, which is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of ELA026 in newly diagnosed, treatment‑naïve adult and pediatric patients with sHLH. ELA026 is the first investigational therapy designed to treat sHLH regardless of underlying trigger, leveraging a novel mechanism of action that targets signal regulatory proteins (SIRP) on immune cells. By selectively depleting pathological myeloid cells and T lymphocytes that drive the cytokine storm and disease severity, ELA026 has the potential to reset the hyperinflammatory cascade at its source. The SURPASS study is actively enrolling at academic medical centers across the U.S. and Europe. Additional information is available at clinicaltrials.gov (NCT05416307).

A second poster, presented by Dr. Catherine Broome (MedStar Georgetown University) and Dr. Daniel Hausrath (Vanderbilt University Medical Center), in collaboration with EpidStrategies, will share results from an Electra-sponsored natural history study characterizing the disease burden and unmet need in patients with sHLH. This study identified a cohort of 232 adult patients over a 16‑year period through electronic health record queries to assess prognostic factors, clinical features, treatment patterns, healthcare utilization, and survival outcomes. The analysis underscored the life-threatening nature of sHLH, its high mortality, and the limited effectiveness of currently available therapies, reinforcing the significant unmet need for improved treatment options.

"We are delighted to connect with the scientific community at ASH (Free ASH Whitepaper) and share the clinical development progress of ELA026 in sHLH," said Kim-Hien Dao, DO, PhD, Chief Medical Officer of Electra Therapeutics. "Every day, patients with sHLH around the world face a devastating prognosis and very limited treatment options. We are committed to generating pivotal data to demonstrate ELA026’s potential to meaningfully improve outcomes for these patients."

Poster Details:

The SURPASS Trial: A Phase 2/3 Registrational Trial of ELA026 in Subjects with Treatment-Naïve Secondary Hemophagocytic Lymphohistiocytosis

Session Number and Name: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Session Date and Time: Saturday, December 6, 5:30 – 7:30 p.m. EST
Location:West Halls B3-B4
Publication Number:#1223

Survival Outcomes of Patients with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at Two Academic Medical Centers in the United States

Session Number and Name: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
Session Date and Time: Monday, December 8, 6:00 – 8:00 p.m. EST
Location:West Halls B3-B4
Publication Number:#6243

ELA026 is the first investigational therapy to receive U.S. Food and Drug Administration Breakthrough Designation (BTD) and European Medicines Agency Priority Medicines (PRIME) designation for sHLH, reflecting its potential to address this life-threatening condition with significant unmet medical need.

About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening hyperinflammatory disease with a lack of treatment options. It can be triggered by cancer, infection, autoimmune disease, or immunotherapy. sHLH is associated with a severe inflammatory response that requires immediate intervention. Without effective treatment, patients may experience multiorgan failure and death. sHLH is associated with high mortality early in the disease course, with malignancy-associated HLH (mHLH) patients having a mortality rate of approximately 50% at two months with available therapies.

(Press release, Electra Therapeutics, DEC 2, 2025, View Source [SID1234661045])

On December 2, 2025 Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health reported it will share new discoveries from their basic science and clinical research programs to advance the understanding of blood cancers, such as lymphoma, leukemia and multiple myeloma, as well as classical hematology disorders at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida (and online). Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, will be featured prominently at this year’s meeting with a total of 93 accepted peer-reviewed scientific abstracts, including 32 oral presentations, 60 poster presentations and 1 satellite symposium.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ASH is a vital platform to present critical breakthroughs that are transforming the science and clinical care in blood diseases, and our prominent involvement reflects our commitment to deliver meaningful progress for patients and the exceptional scientific leadership of our research teams," said Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services and Chief Physician Officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center and System Director of Medical Oncology, RWJBarnabas Health. "Our faculty’s remarkable work highlights the innovation and ground-breaking discoveries that define Rutgers Cancer Institute and RWJBarnabas Health. With the Jack & Sheryl Morris Cancer Center, New Jersey’s only freestanding cancer hospital, now open, we are entering a new era of care and research that brings world-class inpatient and outpatient treatment together with leading science to accelerate discoveries and improve outcomes for patients and families across our state and beyond."

Key scientific contributions from Rutgers Cancer Institute and RWJBarnabas Health at ASH (Free ASH Whitepaper) 2025:

Abs25-2080: Data from a comparative study evaluated PET-adaptive BEACOPP- versus ABVD-based therapies for advanced-stage classic Hodgkin lymphoma (cHL). Researchers compared outcomes from escBEACOPP and ABVD across 2,381 adults using data from four clinical trials and adjusting for baseline risk with the A-HIPI prognostic score. escBEACOPP was associated with significantly better progression-free survival, and multistate modeling showed a lower likelihood of treatment failure both before and after achieving one-year remission. These findings suggest that escBEACOPP offers stronger disease control in PET-adaptive strategies, while the A-HIPI score remains a powerful predictor of risk throughout the treatment course.

Abs25-2547: A study assessed the performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the SWOG S1826 randomized trial of nivolumab-AVD versus brentuximab-AVD. Using locked model parameters and Cox regression analyses, the A-HIPI demonstrated strong prognostic capability, with clear separation of 3-year progression-free survival across predicted risk quartiles and superior discrimination compared with the historic IPS-7. The A-HIPI performed similarly across treatment arms and remained superior in multivariable modeling, confirming it as a more precise, treatment-agnostic tool for risk stratification in newly diagnosed advanced-stage classical Hodgkin lymphoma.

Abs25-12859: Researchers conducted a large multicenter real-world analysis evaluating the use and safety of peripheral intravenous catheters (PIV) versus central venous catheters (CVC) for frontline anthracycline-based chemotherapy in lymphoma. Among 1,414 patients treated with CHOP- or ABVD-based regimens across eight U.S. centers, extravasation was rare in both groups, with only one documented case in the CVC cohort and two suspected cases in the PIV cohort. No significant differences were observed in induration, phlebitis/cellulitis, venous thromboembolism, or erythema. While PIV use was associated with higher rates of local pain/tenderness and infiltration, events were uncommon and self-limited. Overall, PIV access was found to be safe with a low rate of serious complications over more than 9,000 treatments, supporting its selective use despite the common default to CVC placement.

Abs25-8890: A first report from Part 1 of the Phase 3 OLYMPIA-3 study examined odronextamab plus chemotherapy in previously untreated diffuse large B-cell lymphoma (DLBCL). The Part 1A analysis assessed two dose levels in 22 patients, with primary endpoints focused on dose-limiting toxicities and treatment-emergent adverse events. No dose-limiting toxicities occurred, and the safety profile was manageable, with neutropenia, cytokine release syndrome, anemia, and infections as the most common adverse events. All patients experienced Grade ≥3 TEAEs, though CRS events were limited to Grade 1–2 and no tumor lysis syndrome was observed. Preliminary efficacy was encouraging, with ORR of 77.8% and CR rate of 66.7% at DL1 and both ORR and CR of 100% at DL2, with median duration of response not reached. These early results suggest rituximab may not be required to achieve depth of response in this frontline setting.

Abs25-7103: A retrospective real-world evidence study investigated racial and ethnic inequities in access to guideline-preferred first-line therapies for chronic lymphocytic leukemia (CLL). Using data from 4,452 patients in the Flatiron Health Research Database linked with neighborhood-level social determinants of health, researchers found that Black and Hispanic patients were more likely to live in high-deprivation areas and were less likely than White patients to receive NCCN-preferred novel therapies. Structural factors—including residential segregation, socioeconomic status, limited internet access, vehicle ownership, and health insurance—were associated with lower use of preferred first-line treatments. Findings underscore the role of neighborhood-level barriers in limiting equitable access to novel therapies.

The full list of presentations at this year’s American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition can be found here.

(Press release, Rutgers Cancer Institute of New Jersey, DEC 2, 2025, View Source [SID1234661064])

On December 2, 2025 Enterome, a clinical-stage company pioneering OncoMimics peptides, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T cells to fight cancer, reported new survival analyses from Cohort 3 of the Phase 1/2 ROSALIE clinical trial. The data were reported at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The ROSALIE trial is evaluating Enterome’s OncoMimics immune therapy EO2401 in combination with immune checkpoint inhibitor nivolumab, with or without anti-VEGF therapy bevacizumab, in patients with glioblastoma at first progression/recurrence. Top-line data from the trial had previously been released in November 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The analyses demonstrated a statistically significant survival benefit for patients who underwent a second surgery after their first glioblastoma recurrence when treated with EO2401 in combination with nivolumab and bevacizumab, compared with patients who did not undergo surgery (p = 0.027). Importantly, no survival benefit was observed for the supportive therapies, nivolumab or bevacizumab on a stand-alone basis after surgery, compared with no surgery. The investigators concluded in their poster that: "The data indicate that a randomized study evaluating EO2401 is warranted."

The poster was presented at SNO by the lead investigator of the trial, David Reardon M.D., and Professor of Medicine at Harvard Medical School and Clinical Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, under the title: "EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: treatment strategy optimization in the phase 1/2 study EOGBM1-18 / ROSALIE (NCT04116658)". The poster will be made available on the Enterome website.

ROSALIE is a multicenter, open-label, first-in-human study of EO2401 in 100 patients with glioblastoma. EO2401 / nivolumab +/- bevacizumab was well tolerated with a safety profile consistent with the safety profile of nivolumab, and when applicable bevacizumab, except the addition of local administration site reactions. EO2401 plus nivolumab generated fast, strong, and durable specific CD8 T cell immune responses against the EO2401-mimic peptides and target epitopes on tumor associated antigens. Furthermore, the investigators wrote in their poster that the addition of bevacizumab (to EO2401/nivolumab), which exerts strong antiedema properties, and putatively counteracts immunosuppression by VEGF, increased treatment duration and efficacy.

"This finding from the ROSALIE trial in this incredibly challenging patient population is another strong indication of the potential benefit that OncoMimics peptides can offer patients across a broad range of cancers," said Pierre Belichard, Chief Executive Officer of Enterome. "This, and the earlier clinical results make clear that larger, randomized studies of EO2401 are warranted."

EO2401 is an innovative, off-the-shelf OncoMimics multi-targeted in vivo immune therapy composed of three synthetically produced, short non-self HLA-A2 peptides with sequences derived from gut-bacteria (EO2316, EO2317, and EO2318). It is designed to rapidly expand – through peptide molecular mimicry – pre-existing CD8 T cells that cross-react with key glioblastoma tumor associated antigens (TAAs; IL13Ra2, BIRC5/survivin, and FOXM1). EO2401 also includes a universal CD4 helper epitope, UCP2 derived from hTERT, to support and enhance the immune response.

OncoMimics peptides consist of bacteria-derived peptide antigens that closely mimic tumor-associated antigens (TAAs). These antigens induce a fast and potent in vivo expansion of cytotoxic memory CD8+ T cells that were primed by gut bacteria, and are cross-reactive with TAAs. Because the peptides are "non-self", OncoMimics peptides avoid the self-tolerance that limits many cancer immunotherapies, enabling rapid, potent, and durable responses. The synthetically produced peptides are designed in silico, mining Enterome’s proprietary database of 23 million commensal bacteria genes. Each product combines multiple high-affinity peptides to broaden target coverage and mitigate tumor heterogeneity.

OncoMimics peptides are easy to manufacture, store, distribute and administer as an "off-the-shelf" subcutaneous injection. OncoMimics peptides have achieved rapid and potent responses in clinical testing in over 230 patients to date, with a benign safety profile.

(Press release, Enterome, DEC 2, 2025, View Source [SID1234661046])

On December 2, 2025 Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, reported that it will present details from its first-in-human Phase 1 clinical trial of STX-0712, the company’s novel CCR2-CyTAC (Chemokine Receptor Type 2 Cytotoxicity Targeting Chimera) for the treatment of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) in a poster session at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held December 6–9, 2025, in Orlando, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will highlight the design of the ongoing Phase 1, open-label, multicenter study, which is evaluating STX-0712 as monotherapy in patients with refractory or resistant CMML and relapsed or refractory monocytic or monocytic-predominant AML. Primary objectives include safety, determination of dose limiting toxicities, and determination of recommended Phase 2 dose. Secondary objectives include pharmacokinetic and pharmacodynamic characterization of STX-0712, tolerability, and preliminary evidence of antitumor activity. Key elements of the study design include dose escalation using a Bayesian Optimal Interval approach, planned dose expansion, and exploratory analyses assessing CCR2+ cell depletion, biomarkers, immune cell profiling and patient-reported outcomes.

STX-0712 is a CyTAC targeting the G-Protein Coupled Receptor CCR2, a selective marker expressed at high levels on malignant monocytes in these indications, which are key drivers in certain hematologic cancers. By targeting CCR2, STX-0712 is designed to selectively eliminate these malignant cells.

Presentation Details:
Abstract Title: A First-in-Human Study of STX-0712, a CCR2+ Cytotoxicity Targeting Chimera (CyTAC), in Patients with Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)
Presenter: Guillermo Montalban Bravo, M.D., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Date: Sunday, December 7, 2025
Time: 6:00pm-8:00pm EST
Location: Room OCCC- West Halls B3-B4
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II
Abstract Number: 14421

(Press release, Solu Therapeutics, DEC 2, 2025, View Source [SID1234661065])

On December 2, 2025 Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, reported that its work and data will be presented in 12 abstracts at the ASH (Free ASH Whitepaper) 2025 Annual Meeting in Orlando, December 6-9. The work represents novel proprietary approaches using artificial intelligence (AI) for prediction models, transcriptomic signatures, cell-free RNA (cfRNA) analytics, ethnic-ancestry outcomes, circulating cell-free multiple myeloma cells (CMMCs), and more — underscoring GTC’s commitment to innovation in precision hematology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The presented diagnostic innovations provide powerful new tools for stratifying patients and selecting targeted therapy that have the potential of changing the practice of oncology." Said Dr. Maher Albitar the Chief Executive Officer, Chief Medical Officer and Founder of GTC. "The integration of RNA analysis with advanced AI is redefining what precision medicine can achieve. These breakthroughs were made possible by the cooperative business model in diagnostics that was established at the inception of GTC" Dr. Albitar added.

Highlights of the abstracts include:

Liquid-biopsy mutation landscape and its concordance with skin biopsies in cutaneous T-cell lymphoma (abs25-2858)
AI-derived prediction of response and relapse to venetoclax + hypomethylating-agent therapy in acute myeloid leukemia (AML) (abs25-14588)
Integrative clinical and molecular analysis of outcome in elderly African-ancestry AML (abs25-14645)
B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy (abs25-7865)
Somatic mutations and clinical outcomes in primary central nervous system lymphoma among Hispanic and non-Hispanic patients: a study from the UCHMC (University of California Hematologic Malignancies Consortium) (abs25-7950)
Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: clinical and molecular insights (abs25-12597)
Real-world validation of the molecular prognostic risk signature in AML treated with hypomethylating agents + BCL-2 inhibitor (abs25-15523)
Developing artificial-intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for treatment with menin inhibitors (abs25-4126)
Developing artificial-intelligence-based transcriptomic signature for the diagnosis of dark-zone lymphoma in patients without MYC gene rearrangement (abs25-7855)
Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed/refractory multiple myeloma (RRMM) (abs25-12216)
Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia (abs25-4127)
Bone marrow microenvironment overlap between VEXAS and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence (abs25-7376).
At the ASH (Free ASH Whitepaper) meeting, GTC will highlight how its combined tissue and liquid-biopsy portfolio—including cfDNA and cfRNA analytics, transcriptomic signatures, and AI-driven models—supports clinicians and researchers making more informative decisions in treating their patients.

Details on dates and time of the oral and poster presentations are listed on the ASH (Free ASH Whitepaper) and GTC website. Visit GTC in the exhibition hall at booth 2081.

(Press release, Genomic Testing Cooperative, DEC 2, 2025, View Source [SID1234661047])